Acute Phase Proteins as Early Predictors for Immunotherapy Response in Advanced NSCLC: An Explorative Study

Frontiers in Oncology

Sabine Wrenger¹  Sabina Janciauskiene¹  Tobias Welte¹  Michael Thomas³  Petros Christopoulos³  Adriana Rozy⁴  Joanna Chorostowska-Wynimko⁴  Thomas Muley⁵  Marc A. Schneider⁵  Michael Meister⁵ 

[1] Biomedical Research in End Stage and Obstructive Lung Disease Hannover (BREATH), Member of the German Center for Lung Research (DZL), Hannover, Germany;Department of Respiratory Medicine, Hannover Medical School, Hannover, Germany;Department of Thoracic Oncology, Thoraxklinik at University Hospital Heidelberg, Heidelberg, Germany;Laboratory of Molecular Diagnostics and Immunology, National Institute of Tuberculosis and Lung Diseases, Warsaw, Poland;Translational Research Center Heidelberg (TLRC), Member of the German Center for Lung Research (DZL), Heidelberg, Germany;Translational Research Unit, Thoraxklinik at Heidelberg University Hospital, Heidelberg, Germany;

关键词: NSCLC;    checkpoint inhibitors;    immunotherapy;    acute phase proteins;    progression-free survival;   

DOI  :  10.3389/fonc.2022.772076

来源: DOAJ

【 摘 要 】

In the last decade, targeting the immune system became a promising therapy in advanced lung cancer stages. However, in a clinical follow-up, patient responses to immune checkpoint inhibitors widely differ. Peripheral blood is a minimally invasive source of potential biomarkers to explain these differences. We blindly analyzed serum samples from 139 patients with non-small cell lung cancer prior to anti-PD-1 or anti-PD-L1 therapies to assess whether baseline levels of albumin (ALB), alpha-1 acid glycoprotein (AGP), alpha1-antitrypsin (AAT), alpha2-macroglobulin (A2M), ceruloplasmin (CP), haptoglobin (HP), alpha1-antichymotrypsin (ACT), serum amyloid A (SAA), and high-sensitivity C-reactive protein (hs-CRP), have a predictive value for immunotherapy success. Disease progression-free survival (PFS) was calculated based on RECIST 1.1 criteria. A multivariate Cox regression analysis, including serum levels of acute-phase proteins and clinical parameters, revealed that higher pre-therapeutic levels of HP and CP are independent predictors of a worse PFS. Moreover, a combined panel of HP and CP stratified patients into subgroups. We propose to test this panel as a putative biomarker for assessing the success of immunotherapy in patients with NSCLC.

【 授权许可】

Unknown